Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 10/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TKT | P29401 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22600284 | 0.84 | TSHR (0.39) | CYP3A4TSHRCACNA2D1 | |
| SCHEMBL14983862 | 0.71 | CYP11B1 (0.39) | CYP11B1CYP11B2CYP3A4CTSBTKT | |
| SCHEMBL23661902 | 0.71 | CYP11B1 (0.44) | CYP11B1CYP11B2CYP3A4CTSBTSHR | |
| SCHEMBL24261178 | 0.69 | CYP11B1 (0.38) | CYP11B1CYP11B2CYP3A4CTSBTKT | |
| SCHEMBL17480203 | 0.68 | PRMT6 (0.42) | CYP3A4TSHR | |
| SCHEMBL17480206 | 0.68 | SMN1; SMN2 (0.37) | CYP3A4 | |
| SCHEMBL20206079 | 0.68 | CTSB (0.34) | CYP11B1CYP11B2CYP3A4CTSBTKT | |
| SCHEMBL22915466 | 0.68 | LMNA (0.34) | TSHR | |
| SCHEMBL23990848 | 0.67 | CYP11B1 (0.38) | CYP11B1CYP11B2CYP3A4CTSBTKT | |
| SCHEMBL94688 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | CYP11B1 798/4885CYP11B2 898/4885CYP3A4 558/4885 |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | ITGB3, ITGB1, ITGAV | CYP11B1 986/4885CYP11B2 989/4885CYP3A4 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.